Obstructive Lung Disease

Cystic Fibrosis Updates in Care: Part II — The “Sweat Sticker” and Clinician Q&A

By

Tori Rodriguez, MA, LPC, AHC

Publish Date May 21, 2021

In honor of Cystic Fibrosis Awareness Month, we present a 2-part series on treatment updates in the field, including the “sweat sticker.”

Primary Ciliary Dyskinesia: Practical Pearls for Diagnosis

By

Suzanne Bujara

Publish Date January 28, 2019

Recent guidelines set forth by an interdisciplinary panel assembled by the American Thoracic Society sought to demystify primary ciliary dyskinesia and address 4 main diagnostic questions.

Is There an “Ideal” Cystic Fibrosis Candidate for Lung Transplantation?

By

Suzanne Bujara

Publish Date August 23, 2018

Lung transplantation can extend survival in patients with cystic fibrosis who have compromised lung function and increasing exacerbations.

Factors for Gastrointestinal-Related Hospitalizations Among Infants With Cystic Fibrosis

By

Jessica Nye, PhD

Publish Date December 1, 2021

Investigators assessed which factors contribute to risk for GI-related hospitalizations in infants with cystic fibrosis.

Results of a Self-Management Intervention for Cystic Fibrosis

By

Sheila Jacobs

Publish Date November 12, 2021

Can an intervention approach emphasizing habit formation improve treatment adherence and outcomes for patients with cystic fibrosis?

Predictors of Disease Progression and Mortality in Non-IPF Fibrosing ILD

By

Sheila Jacobs

Publish Date October 29, 2021

The researchers sought to identify predictors of disease progression and mortality in non-IPF fILD using criteria from the INBUILD, RELIEF, and uILD trials.

Cyclophosphamide Not Recommended for Acute Exacerbation of Pulmonary Fibrosis

By

Virginia A. Schad, PharmD, RPh

Publish Date October 14, 2021

A clinical trial disproved the notion that adding cyclophosphamide pulses to glucocorticoids was effective for acute exacerbation of IPF.

Elexacaftor-Tezacaftor-Ivacaftor Therapy Effective, Safe in Cystic Fibrosis

By

Sheila Jacobs

Publish Date October 1, 2021

A clinical trial showed ELX-TEZ-IVA had benefits over other CFTR modulators for patients with Phe508del-gating or Phe508del-residual function genotypes.

Aging and Bronchiolitis Obliterans Syndrome Linked to More Interalveolar Pores

By

Bryant Moeller

Publish Date July 30, 2021

Investigators found that aging and bronchiolitis obliterans syndrome are both associated with increased interalveolar communications.

What Affects Prescription Adherence of Patients With Obstructive Lung Disease?

By

Sheila Jacobs

Publish Date July 8, 2021

This studied focused on primary prescription adherence for obstructive lung diseases among adult patients in primary care over a 3-year period.

Trikafta Approval Expanded to Include Younger Cystic Fibrosis Patients

By

Brian Park, PharmD

Publish Date June 17, 2021

The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the F508del mutation and 1 minimal function mutation.